
## W Glenn Mccluggage

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2001893/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology, 2018, 31, 1770-1786.	5.5	739
2	Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology, 2011, 43, 420-432.	0.6	401
3	Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nature Genetics, 2014, 46, 438-443.	21.4	383
4	Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. International Journal of Gynecological Pathology, 2019, 38, S123-S131.	1.4	226
5	p16 Expression in the Female Genital Tract and Its Value in Diagnosis. Advances in Anatomic Pathology, 2006, 13, 8-15.	4.3	220
6	A Panel of Immunohistochemical Stains, Including Carcinoembryonic Antigen, Vimentin, and Estrogen Receptor, Aids the Distinction Between Primary Endometrial and Endocervical Adenocarcinomas. International Journal of Gynecological Pathology, 2002, 21, 11-15.	1.4	189
7	Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology, The, 2018, 19, 1680-1687.	10.7	187
8	Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Seminars in Diagnostic Pathology, 2005, 22, 3-32.	1.5	175
9	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Modern Pathology, 2015, 28, 1101-1122.	5.5	164
10	High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. International Journal of Gynecological Pathology, 2019, 38, S40-S63.	1.4	164
11	Mesonephric Adenocarcinomas of the Uterine Cervix and Corpus. American Journal of Surgical Pathology, 2012, 36, 799-807.	3.7	146
12	Endocervical Glandular Lesions Exhibiting Gastric Differentiation. Advances in Anatomic Pathology, 2013, 20, 227-237.	4.3	139
13	Thyroid Transcription Factor-1 Expression in Endometrial and Endocervical Adenocarcinomas. American Journal of Surgical Pathology, 2007, 31, 1759-1763.	3.7	136
14	A Detailed Immunohistochemical Analysis of a Large Series of Cervical and Vaginal Gastric-type Adenocarcinomas. American Journal of Surgical Pathology, 2016, 40, 636-644.	3.7	129
15	Mullerian Adenosarcoma of the Female Genital Tract. Advances in Anatomic Pathology, 2010, 17, 122-129.	4.3	128
16	An Immunohistochemical Study of Cervical Neuroendocrine Carcinomas: Neoplasms That are Commonly TTF1 Positive and Which May Express CK20 and P63. American Journal of Surgical Pathology, 2010, 34, 525-532.	3.7	127
17	Hormone receptorâ€negative, thyroid transcription factor 1â€positive uterine and ovarian adenocarcinomas: report of a series of mesonephricâ€like adenocarcinomas. Histopathology, 2016, 68, 1013-1020.	2.9	125
18	GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract. American Journal of Surgical Pathology, 2015, 39, 1411-1419.	3.7	124

#	Article	IF	CITATIONS
19	Human papillomavirus prevalence and typeâ€distribution in cervical glandular neoplasias: Results from a <scp>E</scp> uropean multinational epidemiological study. International Journal of Cancer, 2015, 137, 2858-2868.	5.1	122
20	BCOR Internal Tandem Duplication in High-grade Uterine Sarcomas. American Journal of Surgical Pathology, 2018, 42, 335-341.	3.7	118
21	No small surprise–Âsmall cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour. Journal of Pathology, 2014, 233, 209-214.	4.5	117
22	DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. American Journal of Surgical Pathology, 2017, 41, 1178-1187.	3.7	114
23	Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. Modern Pathology, 2015, 28, 1504-1514.	5.5	111
24	Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract. American Journal of Surgical Pathology, 2018, 42, 227-233.	3.7	110
25	Ovarian Neoplasms Composed of Small Round Cells. Advances in Anatomic Pathology, 2004, 11, 288-296.	4.3	109
26	Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Modern Pathology, 2008, 21, 485-490.	5.5	105
27	Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases. American Journal of Surgical Pathology, 2015, 39, 357-364.	3.7	104
28	Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1. American Journal of Surgical Pathology, 2017, 41, 773-780.	3.7	103
29	Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade). International Journal of Gynecological Pathology, 2019, 38, S93-S113.	1.4	99
30	CD56 Is a Sensitive and Diagnostically Useful Immunohistochemical Marker of Ovarian Sex Cord-Stromal Tumors. International Journal of Gynecological Pathology, 2007, 26, 322-327.	1.4	96
31	p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection. Histopathology, 2010, 57, 342-350.	2.9	94
32	Ectopic Prostatic Tissue in the Uterine Cervix and Vagina. American Journal of Surgical Pathology, 2006, 30, 209-215.	3.7	91
33	Pathology of Neuroendocrine Tumours of the Female Genital Tract. Current Oncology Reports, 2017, 19, 59.	4.0	91
34	Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms. Modern Pathology, 2019, 32, 1008-1022.	5.5	89
35	New developments in endocervical glandular lesions. Histopathology, 2013, 62, 138-160.	2.9	87
36	Primary Malignant Melanoma of the Ovary. International Journal of Gynecological Pathology, 2006, 25, 321-329.	1.4	86

#	Article	IF	CITATIONS
37	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecologic Oncology, 2016, 141, 454-460.	1.4	85
38	Loss of expression of <scp>SMARCA</scp> 4 ( <scp>BRG</scp> 1), <scp>SMARCA</scp> 2 ( <scp>BRM</scp> ) and <scp>SMARCB</scp> 1 ( <scp>INI</scp> 1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology. Histopathology, 2017, 70, 359-366.	2.9	84
39	Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology, 2007, 39, 97-111.	0.6	83
40	WT1 is of Value in Ascertaining the Site of Origin of Serous Carcinomas Within the Female Genital Tract. International Journal of Gynecological Pathology, 2004, 23, 97-99.	1.4	82
41	Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCT) Lack the JAZF1-JJAZ1 Translocation Frequently Seen in Endometrial Stromal Tumors. American Journal of Surgical Pathology, 2009, 33, 1206-1212.	3.7	82
42	Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines. Clinical Cancer Research, 2020, 26, 3908-3917.	7.0	82
43	Ewing family of tumours involving the vulva and vagina: report of a series of four cases. Journal of Clinical Pathology, 2007, 60, 674-680.	2.0	78
44	Microcystic Stromal Tumor. American Journal of Surgical Pathology, 2015, 39, 1420-1426.	3.7	78
45	Luteinized Thecomas (Thecomatosis) of the Type Typically Associated With Sclerosing Peritonitis. American Journal of Surgical Pathology, 2008, 32, 1273-1290.	3.7	77
46	The developing spectrum of gastric-type cervical glandular lesions. Pathology, 2018, 50, 122-133.	0.6	77
47	A multistep model for ovarian tumorigenesis: the value of mutation analysis in theKRAS andBRAF genes. Journal of Pathology, 2004, 203, 617-619.	4.5	76
48	Patterns of p53 immunoreactivity in endometrial carcinomas: †all or nothing' staining is of importance. Histopathology, 2011, 59, 786-788.	2.9	76
49	Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract. American Journal of Surgical Pathology, 2021, 45, 498-506.	3.7	76
50	Low-Grade Ovarian Serous Neoplasms (Low-Grade Serous Carcinoma and Serous Borderline Tumor) Associated With High-Grade Serous Carcinoma or Undifferentiated Carcinoma. American Journal of Surgical Pathology, 2012, 36, 368-375.	3.7	75
51	Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: AÂsystematic review and meta-analysis. PLoS ONE, 2020, 15, e0232231.	2.5	73
52	Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms: Table 1. Journal of Clinical Pathology, 2012, 65, 596-600.	2.0	71
53	Highâ€grade serous carcinoma of tuboâ€ovarian origin: recent developments. Histopathology, 2017, 71, 339-356.	2.9	71
54	Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab Journal of Clinical Oncology, 2014, 32, 5502-5502.	1.6	71

#	Article	IF	CITATIONS
55	Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary. American Journal of Surgical Pathology, 2017, 41, 685-695.	3.7	70
56	Assignment of primary site in highâ€grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology, 2014, 65, 149-154.	2.9	69
57	Metastatic Carcinomas in the Cervix Mimicking Primary Cervical Adenocarcinoma and Adenocarcinoma In Situ. American Journal of Surgical Pathology, 2010, 34, 735-741.	3.7	68
58	HPV-negative Gastric Type Adenocarcinoma In Situ of the Cervix. American Journal of Surgical Pathology, 2017, 41, 1023-1033.	3.7	68
59	Embryonal Rhabdomyosarcoma (Botryoid Type) of the Uterine Corpus and Cervix in Adult Women. American Journal of Surgical Pathology, 2013, 37, 344-355.	3.7	66
60	Yolk sac tumours of the female genital tract in older adults derive commonly from somatic epithelial neoplasms: somatically derived yolk sac tumours. Histopathology, 2016, 69, 739-751.	2.9	66
61	Immunohistochemical and Functional Biomarkers of Value in Female Genital Tract Lesions. International Journal of Gynecological Pathology, 2006, 25, 101-120.	1.4	65
62	Ovarian Seromucinous Carcinoma. American Journal of Surgical Pathology, 2015, 39, 983-992.	3.7	64
63	Primary Ovarian Carcinoid Tumors may Express CDX-2: A Potential Pitfall in Distinction From Metastatic Intestinal Carcinoid Tumors Involving the Ovary. International Journal of Gynecological Pathology, 2009, 28, 41-48.	1.4	63
64	Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. Gynecologic Oncology, 2016, 141, 195-198.	1.4	60
65	HMGA2 is a Sensitive But Not Specific Immunohistochemical Marker of Vulvovaginal Aggressive Angiomyxoma. American Journal of Surgical Pathology, 2010, 34, 1037-1042.	3.7	59
66	Epithelial–mesenchymal transition in carcinomas of the female genital tract. Histopathology, 2013, 62, 31-43.	2.9	59
67	Recent Developments in Non–HPV-related Adenocarcinomas of the Lower Female Genital Tract and Their Precursors. Advances in Anatomic Pathology, 2016, 23, 58-69.	4.3	58
68	Uterine Serous Carcinomas Frequently Metastasize to the Fallopian Tube and Can Mimic Serous Tubal Intraepithelial Carcinoma. American Journal of Surgical Pathology, 2017, 41, 161-170.	3.7	58
69	Endometrial stromal sarcomas with extensive endometrioid glandular differentiation: report of a series with emphasis on the potential for misdiagnosis and discussion of the differential diagnosis. Histopathology, 2009, 54, 365-373.	2.9	57
70	A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus. Modern Pathology, 2016, 29, S78-S91.	5.5	57
71	Rhabdomyosarcoma of the uterus: Report of two cases, including one of the spindle cell variant. International Journal of Gynecological Cancer, 2002, 12, 128-132.	2.5	56
72	Ovarian Combined Low-grade Serous and Mesonephric-like Adenocarcinoma: Further Evidence for A Mullerian Origin of Mesonephric-like Adenocarcinoma. International Journal of Gynecological Pathology, 2020, 39, 84-92.	1.4	55

#	Article	IF	CITATIONS
73	Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial Journal of Clinical Oncology, 2013, 31, 5500-5500.	1.6	55
74	A review and update of morphologically bland vulvovaginal mesenchymal lesions. International Journal of Gynecological Pathology, 2005, 24, 26-38.	1.4	55
75	WT1, p53 and hormone receptor expression in uterine serous carcinoma. Histopathology, 2009, 55, 478-482.	2.9	54
76	The Expression and Diagnostic Utility of p63 in the Female Genital Tract. Advances in Anatomic Pathology, 2009, 16, 316-321.	4.3	54
77	Endometrial Carcinoma, Grossing and Processing Issues: Recommendations of the International Society of Gynecologic Pathologists. International Journal of Gynecological Pathology, 2019, 38, S9-S24.	1.4	54
78	Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. Journal of Clinical Pathology, 2010, 63, 169-173.	2.0	53
79	Small-Cell Carcinoma of the Ovary of Hypercalcemic Type (Malignant Rhabdoid Tumor of the Ovary). Surgical Pathology Clinics, 2016, 9, 215-226.	1.7	53
80	Tubulo-squamous Polyp. American Journal of Surgical Pathology, 2007, 31, 1013-1019.	3.7	52
81	The pathology of and controversial aspects of ovarian borderline tumours. Current Opinion in Oncology, 2010, 22, 462-472.	2.4	52
82	Data Set for Reporting of Endometrial Carcinomas. International Journal of Gynecological Pathology, 2013, 32, 45-65.	1.4	52
83	Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small ell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. Histopathology, 2016, 69, 727-738.	2.9	52
84	Uterine tumour resembling ovarian sex cord tumour: first report of a large series with followâ€up. Histopathology, 2017, 71, 751-759.	2.9	52
85	International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. International Journal of Gynecological Pathology, 2019, 38, S114-S122.	1.4	52
86	Primary Ovarian Mucinous Tumors With Signet Ring Cells. American Journal of Surgical Pathology, 2008, 32, 1373-1379.	3.7	51
87	Misplaced Skene's Glands. International Journal of Gynecological Pathology, 2011, 30, 605-612.	1.4	51
88	Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Recommendations from the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology, 2019, 38, S25-S39.	1.4	51
89	Endometriosisâ€related pathology: a discussion of selected uncommon benign, premalignant and malignant lesions. Histopathology, 2020, 76, 76-92.	2.9	51
90	A Strategy for Defining Biologically Relevant Levels of p53 Protein Expression in Clinical Samples with Reference to Endometrial Neoplasia. International Journal of Gynecological Pathology, 2005, 24, 307-312.	1.4	49

#	Article	IF	CITATIONS
91	Stratified mucinâ€producing intraepithelial lesion (SMILE): report of a case series with associated pathological findings. Histopathology, 2015, 66, 658-663.	2.9	49

## 92 Ovarian Sertoli-Leydig Cell Tumors With Pseudoendometrioid Tubules (Pseudoendometrioid) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702

93	The secondary Müllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. Pathology, 2015, 47, 423-431.	0.6	48
94	Germ cell tumour growth patterns originating from clear cell carcinomas of the ovary and endometrium: a comparative immunohistochemical study favouring their origin from somatic stem cells. Histopathology, 2018, 72, 634-647.	2.9	48
95	ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus. American Journal of Surgical Pathology, 2018, 42, 1353-1359.	3.7	48
96	Guidelines to Aid in the Distinction of Endometrial and Endocervical Carcinomas, and the Distinction of Independent Primary Carcinomas of the Endometrium and Adnexa From Metastatic Spread Between These and Other Sites. International Journal of Gynecological Pathology, 2019, 38, S75-S92.	1.4	48
97	Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT) Commonly Exhibits Positivity With Sex Cord Markers FOXL2 and SF-1 but Lacks FOXL2 and DICER1 Mutations. International Journal of Gynecological Pathology, 2016, 35, 301-308.	1.4	46
98	Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology, 2022, 80, 762-778.	2.9	46
99	Paraganglioma of the Ovary. American Journal of Surgical Pathology, 2006, 30, 600-605.	3.7	44
100	Endometrial Intestinal Metaplasia. International Journal of Gynecological Pathology, 2011, 30, 492-496.	1.4	44
101	Papillary Proliferation of the Endometrium. American Journal of Surgical Pathology, 2013, 37, 167-177.	3.7	44
102	SMARCB1-deficient Vulvar Neoplasms. American Journal of Surgical Pathology, 2015, 39, 836-849.	3.7	44
103	Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma. International Journal of Gynecological Pathology, 2016, 35, 230-237.	1.4	44
104	Data Set for the Reporting of Carcinomas of the Cervix: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International Journal of Gynecological Pathology, 2018, 37, 205-228.	1.4	44
105	Ovarian Spindle Cell Lesions. Advances in Anatomic Pathology, 2007, 14, 305-319.	4.3	43
106	Significant Variation in the Assessment of Cervical Involvement in Endometrial Carcinoma. American Journal of Surgical Pathology, 2011, 35, 289-294.	3.7	43
107	Premalignant lesions of the lower female genital tract: cervix, vagina and vulva. Pathology, 2013, 45, 214-228.	0.6	43
108	Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma. Modern Pathology, 2020, 33, 1207-1219.	5.5	43

#	Article	IF	CITATIONS
109	Prognostic factors in ovarian adult granulosa cell tumour. Journal of Clinical Pathology, 2008, 61, 881-884.	2.0	42
110	Embryonal Rhabdomyosarcoma of the Ovary and Fallopian Tube. American Journal of Surgical Pathology, 2020, 44, 738-747.	3.7	42
111	Predicting Clinical Outcome in Patients Diagnosed with Synchronous Ovarian and Endometrial Cancer. Clinical Cancer Research, 2008, 14, 5840-5848.	7.0	41
112	Increased p16 Expression in High-grade Serous and Undifferentiated Carcinoma Compared With Other Morphologic Types of Ovarian Carcinoma. International Journal of Gynecological Pathology, 2009, 28, 179-186.	1.4	41
113	Ovarian Cellular Fibromas Lack FOXL2 Mutations. American Journal of Surgical Pathology, 2013, 37, 1450-1455.	3.7	41
114	Ovarian Microcystic Stromal Tumors Are Characterized by Alterations in the Beta-Catenin-APC Pathway and May be an Extracolonic Manifestation of Familial Adenomatous Polyposis. American Journal of Surgical Pathology, 2018, 42, 137-139.	3.7	41
115	Tumor Typing of Endocervical Adenocarcinoma: Contemporary Review and Recommendations From the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology, 2021, 40, S75-S91.	1.4	41
116	Combined Adult Granulosa Cell Tumor and Mucinous Cystadenoma of the Ovary: Granulosa Cell Tumor with Heterologous Mucinous Elements. International Journal of Gynecological Pathology, 2005, 24, 224-227.	1.4	39
117	Assessment of a new system for primary site assignment in highâ€grade serous carcinoma of the fallopian tube, ovary, and peritoneum. Histopathology, 2015, 67, 331-337.	2.9	39
118	A Critical Appraisal of the Value of Immunohistochemistry in Diagnosis of Uterine Neoplasms. Advances in Anatomic Pathology, 2004, 11, 162-171.	4.3	38
119	Vulval Intraepithelial Neoplasia With Mucinous Differentiation. American Journal of Surgical Pathology, 2009, 33, 945-949.	3.7	37
120	Cyclin D1 Does Not Distinguish YWHAE-NUTM2 High-grade Endometrial Stromal Sarcoma From Undifferentiated Endometrial Carcinoma. American Journal of Surgical Pathology, 2015, 39, 722-724.	3.7	37
121	Clinical, morphological and immunohistochemical evidence that smallâ€cell carcinoma of the ovary of hypercalcaemic type ( <scp>SCCOHT</scp> ) may be a primitive germâ€cell neoplasm. Histopathology, 2017, 70, 1147-1154.	2.9	36
122	Uterine Angioleiomyomas: A Report of 3 Cases of a Distinctive Benign Leiomyoma Variant. International Journal of Surgical Pathology, 2007, 15, 262-265.	0.8	35
123	Massive Vulval Edema Secondary to Obesity and Immobilization: A Potential Mimic of Aggressive Angiomyxoma. International Journal of Gynecological Pathology, 2008, 27, 447-452.	1.4	35
124	Reactive Fibroblastic and Myofibroblastic Proliferation of the Vulva (Cyclist's Nodule). American Journal of Surgical Pathology, 2011, 35, 110-114.	3.7	35
125	Cervical embryonal rhabdomyosarcoma and ovarian Sertoli-Leydig cell tumour: a more than coincidental association of two rare neoplasms?. Journal of Clinical Pathology, 2006, 60, 326-328.	2.0	34
126	Rare non-epithelial ovarian neoplasms: Pathology, genetics and treatment. Gynecologic Oncology, 2016, 142, 190-198.	1.4	34

#	Article	IF	CITATIONS
127	Reclassifying endometrial carcinomas with a combined morphological and molecular approach. Current Opinion in Oncology, 2019, 31, 411-419.	2.4	34
128	The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma. International Journal of Gynecological Pathology, 2017, 36, 172-179.	1.4	33
129	Oxyphilic Adenomatoid Tumor of the Ovary. International Journal of Gynecological Pathology, 2007, 26, 16-20.	1.4	32
130	Composite cervical adenocarcinoma composed of adenoma malignum and gastric type adenocarcinoma (dedifferentiated adenoma malignum) in a patient with Peutz Jeghers syndrome. Journal of Clinical Pathology, 2010, 63, 935-941.	2.0	32
131	Peritoneal mesothelial hyperplasia associated with gynaecological disease: a potential diagnostic pitfall that is commonly associated with endometriosis. Journal of Clinical Pathology, 2011, 64, 313-318.	2.0	32
132	Do FIGO Stage IA and Small (â‰û cm) IB1 Cervical Adenocarcinomas Have a Good Prognosis and Warrant Less Radical Surgery?. International Journal of Gynecological Cancer, 2012, 22, 291-295.	2.5	32
133	Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer. Histopathology, 2019, 75, 128-136.	2.9	32
134	Micropapillary Cervical Adenocarcinoma. American Journal of Surgical Pathology, 2019, 43, 802-809.	3.7	32
135	Ten problematical issues identified by pathology review for multidisciplinary gynaecological oncology meetings. Journal of Clinical Pathology, 2012, 65, 293-301.	2.0	31
136	The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians. International Journal of Gynecological Pathology, 2017, 36, 230-239.	1.4	31
137	The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis. Journal of Pathology, 2010, 220, 5-6.	4.5	30
138	Primary Endometrial Yolk Sac Tumor With Endodermal-Intestinal Differentiation Masquerading as Metastatic Colorectal Adenocarcinoma. International Journal of Gynecological Pathology, 2016, 35, 316-320.	1.4	30
139	<i>GREB1â€CTNNB1</i> fusion transcript detected by RNAâ€sequencing in a uterine tumor resembling ovarian sex cord tumor (UTROSCT): A novel <i>CTNNB1</i> rearrangement. Genes Chromosomes and Cancer, 2019, 58, 155-163.	2.8	30
140	<scp><i>NTRK</i></scp> and other recently described kinase fusion positive uterine sarcomas: A review of a group of rare neoplasms. Genes Chromosomes and Cancer, 2021, 60, 147-159.	2.8	30
141	Review of findings in prophylactic gynaecological specimens in <scp>L</scp> ynch syndrome with literature review and recommendations for grossing. Histopathology, 2014, 65, 228-239.	2.9	29
142	Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer. International Journal of Gynecological Cancer, 2016, 26, 431-436.	2.5	29
143	<scp>DICER1â€associated</scp> embryonal rhabdomyosarcoma and adenosarcoma of the gynecologic tract: Pathology, molecular genetics, and indications for molecular testing. Genes Chromosomes and Cancer, 2021, 60, 217-233.	2.8	29
144	Vascular Involvement in Adenomyosis: Report of a Large Series of a Common Phenomenon With Observations on the Pathogenesis of Adenomyosis. International Journal of Gynecological Pathology, 2010, 29, 117-121.	1.4	28

1

#	Article	IF	CITATIONS
145	Which staging system to use for gynaecological cancers: a survey with recommendations for practice in the UK. Journal of Clinical Pathology, 2010, 63, 768-770.	2.0	28
146	Microscopic extraovarian sex cord proliferations: an undescribed phenomenon. Histopathology, 2015, 66, 555-564.	2.9	28
147	DICER1 hotâ€spot mutations in ovarian gynandroblastoma. Histopathology, 2018, 73, 306-313.	2.9	28
148	Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations. Modern Pathology, 2021, 34, 1213-1225.	5.5	28
149	Papillary Syncytial Metaplasia Associated With Endometrial Breakdown Exhibits an Immunophenotype That Overlaps With Uterine Serous Carcinoma. International Journal of Gynecological Pathology, 2012, 31, 206-210.	1.4	27
150	Thyroid transcription factorâ€1 ( <scp>TTF</scp> â€1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus. Histopathology, 2014, 64, 840-846.	2.9	27
151	Myoepithelial neoplasms involving the vulva and vagina: report of 4 cases. Human Pathology, 2009, 40, 1747-1753.	2.0	26
152	Diffuse CK7, CAM5.2 and BerEP4 positivity in pagetoid squamous cell carcinoma <i>in situ</i> (pagetoid) Tj ETQ 2013, 62, 511-514.	0 0 0 rgB <sup>-</sup> 2.9	[ /Overlock ] 26
153	Myogenin expression in vulvovaginal spindle cell lesions: analysis of a series of cases with an emphasis on diagnostic pitfalls. Histopathology, 2013, 63, 545-550.	2.9	26
154	Adult Granulosa Cell Tumor With High-grade Transformation. American Journal of Surgical Pathology, 2019, 43, 1229-1238.	3.7	26
155	A novel group of HPV-related adenocarcinomas of the lower anogenital tract (vagina, vulva, and) Tj ETQq1 1 0.78 Pathology, 2020, 33, 944-952.	4314 rgBT 5.5	/Overlock 1 26
156	Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium. American Journal of Surgical Pathology, 2020, 44, 1541-1548.	3.7	26
157	High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities. Modern Pathology, 2020, 33, 1861-1870.	5.5	26
158	Extrauterine Mesonephric-like Neoplasms. American Journal of Surgical Pathology, 2022, 46, 124-133.	3.7	26
159	HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. Histopathology, 2012, 60, 547-553.	2.9	25
160	Molecular subtyping of mammaryâ€ŀike adenocarcinoma of the vulva shows molecular similarity to breast carcinomas. Histopathology, 2017, 71, 446-452.	2.9	25
161	Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC) Journal of Clinical Oncology, 2015, 33, 5528-5528.	1.6	25
162	Endometrial Stromal Sarcomas With True Papillae and Pseudopapillae. International Journal of Gynecological Pathology, 2008, 27, 555-561.	1.4	24

#	Article	IF	CITATIONS
163	Low-grade Epithelial-Myoepithelial Carcinoma of Bartholin Gland: Report of 2 Cases of a Distinctive Neoplasm Arising in the Vulvovaginal Region. International Journal of Gynecological Pathology, 2009, 28, 286-291.	1.4	24
164	Primary Vaginal Gastric-type Adenocarcinoma and Vaginal Adenosis Exhibiting Gastric Differentiation. American Journal of Surgical Pathology, 2018, 42, 958-970.	3.7	24
165	Pathologic Staging of Endometrial Carcinomas: Selected Areas of Difficulty. Advances in Anatomic Pathology, 2018, 25, 71-84.	4.3	24
166	Expanding the morphological spectrum of ovarian microcystic stromal tumour. Histopathology, 2019, 74, 443-451.	2.9	24
167	Adenomyomas of the uterine cervix: report of a cohort including endocervical and novel variants. Histopathology, 2015, 66, 420-429.	2.9	23
168	A Rare Case of HPV-Negative Cervical Squamous Cell Carcinoma. International Journal of Gynecological Pathology, 2015, 34, 208-212.	1.4	22
169	DICER1-associated sarcomas: towards a unified nomenclature. Modern Pathology, 2021, 34, 1226-1228.	5.5	22
170	Intravascular Adenomyomatosis. American Journal of Surgical Pathology, 2013, 37, 1395-1400.	3.7	21
171	Adult granulosa cell tumourâ€like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of <i><scp>FOXL</scp>2</i> mutation status. Histopathology, 2014, 64, 626-632.	2.9	21
172	Embryonal rhabdomyosarcoma of the uterine corpus: a clinicopathological and molecular analysis of 21 cases highlighting a frequent association with DICER1 mutations. Modern Pathology, 2021, 34, 1750-1762.	5.5	21
173	Atypical reactive proliferation of endocervix: a common lesion associated with endometrial carcinoma and likely related to prior endometrial sampling. Modern Pathology, 2006, 19, 470-474.	5.5	20
174	The C134W (402 C>G) <i>FOXL2</i> mutation is absent in ovarian gynandroblastoma: insights into the genesis of an unusual tumour. Histopathology, 2012, 60, 838-842.	2.9	20
175	Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line. Nucleic Acids Research, 2016, 44, e137-e137.	14.5	20
176	Mesonephric-like Adenocarcinoma of the Female Genital Tract: From Morphologic Observations to a Well-characterized Carcinoma With Aggressive Clinical Behavior. Advances in Anatomic Pathology, 2022, 29, 208-216.	4.3	20
177	Mullerian papilloma–like proliferation arising in cystic pelvic endosalpingiosis. Human Pathology, 2002, 33, 944-946.	2.0	19
178	Endometrial Adenocarcinoma With Signet Ring Cells. International Journal of Gynecological Pathology, 2010, 29, 579-582.	1.4	19
179	Towards developing a meaningful grading system for cervical squamous cell carcinoma. Journal of Pathology: Clinical Research, 2018, 4, 81-85.	3.0	19
180	Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. Histopathology, 2019, 75, 813-824.	2.9	19

#	Article	IF	CITATIONS
181	A Distinctive Adnexal (Usually Paratubal) Neoplasm Often Associated With Peutz-Jeghers Syndrome and Characterized by STK11 Alterations (STK11 Adnexal Tumor). American Journal of Surgical Pathology, 2021, 45, 1061-1074.	3.7	19
182	Paediatric ovarian tumours and their associated cancer susceptibility syndromes. Journal of Medical Genetics, 2018, 55, 1-10.	3.2	19
183	Primary Vaginal Mucinous Adenocarcinoma of Gastric Type Arising in Adenosis. International Journal of Gynecological Pathology, 2012, 31, 184-191.	1.4	18
184	Expression of Markers of Müllerian Clear Cell Carcinoma in Primary Cervical and Vaginal Gastric-type Adenocarcinomas. International Journal of Gynecological Pathology, 2019, 38, 276-282.	1.4	18
185	The Evolving Spectrum of Precursor Lesions of Cervical Adenocarcinomas. Advances in Anatomic Pathology, 2020, 27, 278-293.	4.3	18
186	Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. International Journal of Gynecological Cancer, 2002, 12, 62-65.	2.5	17
187	Immunohistochemical markers as a diagnostic aid in ovarian pathology. Diagnostic Histopathology, 2008, 14, 335-351.	0.4	17
188	Florid Vulval Paget Disease Exhibiting p16 Immunoreactivity and Mimicking Classic VIN. International Journal of Gynecological Pathology, 2013, 32, 221-227.	1.4	17
189	Recently characterized molecular events in uncommon gynaecological neoplasms and their clinical importance. Histopathology, 2016, 69, 903-913.	2.9	17
190	Defining the molecular evolution of extrauterine high grade serous carcinoma. Gynecologic Oncology, 2019, 155, 305-317.	1.4	17
191	p53 immunohistochemical analysis of fusionâ€positive uterine sarcomas. Histopathology, 2021, 78, 805-813.	2.9	17
192	HMGA2 Is a Useful Marker of Vulvovaginal Aggressive Angiomyxoma But May Be Positive in Other Mesenchymal Lesions at This Site. International Journal of Gynecological Pathology, 2021, 40, 185-189.	1.4	17
193	Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes. World Journal of Clinical Oncology, 2020, 11, 868-889.	2.3	17
194	High grade serous carcinoma of the ovary with a yolk sac tumour component in a postmenopausal woman: report of an extremely rare phenomenon. Journal of Clinical Pathology, 2012, 65, 853-854.	2.0	16
195	Neuroendocrine Tumors of the Fallopian Tube: Report of a Case Series and Review of the Literature. International Journal of Gynecological Pathology, 2019, 38, 78-84.	1.4	15
196	Ovarian mucinous and seromucinous neoplasms: problematic aspects and modern diagnostic approach. Histopathology, 2022, 80, 255-278.	2.9	15
197	Rare DICER1 and Absent FOXL2 Mutations Characterize Ovarian Juvenile Granulosa Cell Tumors. American Journal of Surgical Pathology, 2021, 45, 223-229.	3.7	15
198	Ovarian Adenosarcoma With Extensive Deciduoid Morphology Arising in Endometriosis: A Case Report. International Journal of Gynecological Pathology, 2008, 27, 398-401.	1.4	14

#	Article	IF	CITATIONS
199	Myxoid Change of the Myometrium and Cervical Stroma: Description of a Hitherto Unreported Non-neoplastic Phenomenon With Discussion of Myxoid Uterine Lesions. International Journal of Gynecological Pathology, 2010, 29, 351-357.	1.4	14
200	BCL2 and Keratin 5 Define the Uterine-Cervix-Isthmus Junction, a Transition Between Endocervical and Tubal-Like Epithelium. International Journal of Gynecological Pathology, 2013, 32, 122-130.	1.4	14
201	Unclassifiable Malignant Extraovarian Sex Cord-Stromal Tumors: Report of 3 Cases and Review of Extraovarian Sex Cord-Stromal Tumors. International Journal of Gynecological Pathology, 2017, 36, 438-446.	1.4	14
202	SWI/SNF-deficient malignancies of the female genital tract. Seminars in Diagnostic Pathology, 2021, 38, 199-211.	1.5	14
203	Uterine Neoplasms Composed of Rhabdoid Cells Do Not Exhibit Loss of INI1 Immunoreactivity and Are Not Related to Childhood Malignant Rhabdoid Tumor. International Journal of Gynecological Pathology, 2008, PAP, 236-42.	1.4	14
204	DICER1-sarcoma: an emerging entity. Modern Pathology, 2021, 34, 2096-2097.	5.5	14
205	Ovarian Serous Cystadenofibroma With Stromal Sex Cord Elements. International Journal of Gynecological Pathology, 2006, 25, 336-339.	1.4	13
206	Symplastic Atypia in Neoplastic and Non-neoplastic Endometrial Stroma: Report of 3 Cases With a Review of Atypical Symplastic Cells Within the Female Genital Tract. International Journal of Gynecological Pathology, 2009, 28, 334-337.	1.4	13
207	Luteinized Thecomas (Thecomatosis) Associated With Sclerosing Peritonitis Exhibit Positive Staining With Sex Cord Markers Steroidogenic Factor-1 (SF-1) and FOXL2. American Journal of Surgical Pathology, 2013, 37, 1458-1459.	3.7	13
208	Fallopian Tube Mucosal Involvement in Cervical Gastric-type Adenocarcinomas. American Journal of Surgical Pathology, 2018, 42, 813-820.	3.7	13
209	Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HCSC): Implications for Assigning Primary Site and FIGO Stage. International Journal of Gynecological Pathology, 2018, 37, 324-330.	1.4	13
210	Grading of Endocervical Adenocarcinomas: Review of the Literature and Recommendations From the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology, 2021, 40, S66-S74.	1.4	13
211	Endometrial Gastric-type Carcinoma. American Journal of Surgical Pathology, 2020, 44, 1736-1737.	3.7	13
212	Primary High-grade Serous Carcinoma Arising in the Urethra or Urethral Diverticulum. International Journal of Gynecological Pathology, 2013, 32, 141-145.	1.4	12
213	A Case of HPV-negative Intestinal-type Endocervical Adenocarcinoma In Situ With Coexisting Multifocal Intestinal and Gastric Metaplasia. American Journal of Surgical Pathology, 2014, 38, 289-291.	3.7	12
214	<scp>CD</scp> 34 expression in undifferentiated endometrial carcinoma. Histopathology, 2016, 69, 894-897.	2.9	12
215	Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging. Modern Pathology, 2018, 31, 652-659.	5.5	12
216	The dilemma of early preventive oophorectomy in familial small cell carcinoma of the ovary of hypercalcemic type. Gynecologic Oncology Reports, 2019, 28, 47-49.	0.6	12

#	Article	IF	CITATIONS
217	Uterine Endometrial Stromal Tumors With Limited Infiltration: First Report of a Case Series Indicating Potential for Malignant Behavior. International Journal of Gynecological Pathology, 2020, 39, 221-226.	1.4	12
218	Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary. American Journal of Surgical Pathology, 2021, 45, 374-383.	3.7	12
219	The Value of DICER1 Mutation Analysis in "Subtle―Diagnostically Challenging Embryonal Rhabdomyosarcomas of the Uterine Cervix. International Journal of Gynecological Pathology, 2021, 40, 435-440.	1.4	12
220	Ovarian Serous Cystadenofibroma With Signet Ring-Stromal Cells. International Journal of Gynecological Pathology, 2010, 29, 411-414.	1.4	11
221	Reproducibility of measurement of myometrial invasion in endometrial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 63-68.	2.8	11
222	Somatic genetic alterations in synchronous and metachronous lowâ€grade serous tumours and highâ€grade carcinomas of the adnexa. Histopathology, 2019, 74, 638-650.	2.9	11
223	DICER1-associated sarcomas at different sites exhibit morphological overlap arguing for a unified nomenclature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 431-433.	2.8	11
224	Uterine Adenolipoleiomyoma: A Rare Hamartomatous Lesion. International Journal of Gynecological Pathology, 2000, 19, 183-185.	1.4	10
225	Juvenile granulosa cell tumor arising in ovarian adenosarcoma: an unusual form of sarcomatous overgrowth. Human Pathology, 2015, 46, 614-619.	2.0	10
226	YWHAE-NUTM2A/B Translocated High-grade Endometrial Stromal Sarcoma Commonly Expresses CD56 and CD99. International Journal of Gynecological Pathology, 2019, 38, 528-532.	1.4	10
227	Skene's Gland Derivatives in the Female Genital Tract and Cervical Adenoid Basal Carcinoma are Consistently Positive With Prostatic Marker NKX3.1. International Journal of Gynecological Pathology, 2021, 40, 400-407.	1.4	10
228	Problematic areas in the reporting of endometrial carcinomas in hysterectomy specimens. Diagnostic Histopathology, 2009, 15, 571-581.	0.4	9
229	Multifocal Uterine Myxoid Change. International Journal of Gynecological Pathology, 2012, 31, 580-583.	1.4	9
230	Epidermal growth factor receptor ( <scp>EGFR</scp> ), <scp>HER</scp> 2 and insulinâ€like growth factorâ€1 receptor ( <scp>IGF</scp> â€1R) status in ovarian adult granulosa cell tumours. Histopathology, 2014, 64, 633-638.	2.9	9
231	Differential expression of Eâ€cadherin and catenins in ovarian sex cord stromal tumours. Histopathology, 2016, 69, 298-306.	2.9	9
232	SWI/SNF protein and claudinâ€4 expression in anaplastic carcinomas arising in mucinous tumours of the ovary and retroperitoneum. Histopathology, 2020, 77, 231-239.	2.9	9
233	The association between MAD2 and prognosis in cancer: a systematic review and meta-analyses. Oncotarget, 2017, 8, 102223-102234.	1.8	9
234	Cervical Adenocarcinoma Resembling Breast Lobular Carcinoma. International Journal of Gynecological Pathology, 2010, 29, 594-599.	1.4	8

#	Article	IF	CITATIONS
235	Miscellaneous disorders involving the endometrium. Seminars in Diagnostic Pathology, 2010, 27, 287-310.	1.5	8
236	Ovarian borderline tumours: a review with comparison of serous and mucinous types. Diagnostic Histopathology, 2014, 20, 333-350.	0.4	8
237	Serous Tubal Intraepithelial Carcinoma (STIC)-like Lesions Arising in Ovarian Serous Cystadenofibroma. International Journal of Gynecological Pathology, 2015, 34, 535-540.	1.4	8
238	p16 as a prognostic indicator in ovarian/tubal highâ€grade serous carcinoma. Histopathology, 2016, 68, 615-618.	2.9	8
239	Low-grade Serous Carcinoma Arising in Inguinal Nodal Endosalpingiosis: Report of 2 Cases and Literature Review. International Journal of Gynecological Pathology, 2020, 39, 273-278.	1.4	8
240	Somatic tumour testing establishes that bilateral <i>DICER1</i> â€associated ovarian Sertoli–Leydig cell tumours represent independent primary neoplasms. Histopathology, 2020, 77, 223-230.	2.9	8
241	Ovarian seromucinous cystadenomas and adenofibromas: first report of a case series. Histopathology, 2021, 78, 445-452.	2.9	8
242	Progress in the pathological arena of gynecological cancers. International Journal of Gynecology and Obstetrics, 2021, 155, 107-114.	2.3	8
243	Ovarian microcystic stromal tumour: from morphological observations to syndromic associations. Histopathology, 2022, 80, 898-904.	2.9	8
244	Survival outcomes in endometrial cancer patients according to diabetes: a systematic review and meta-analysis. BMC Cancer, 2022, 22, 427.	2.6	8
245	BRCA1 Immunohistochemical Staining as a Prognostic Indicator in Uterine Serous Carcinoma. International Journal of Gynecological Cancer, 2013, 23, 113-118.	2.5	7
246	Adenomyomatous Polyp of the Endometrium With Prominent Epithelioid Smooth Muscle Differentiation. International Journal of Surgical Pathology, 2014, 22, 358-363.	0.8	7
247	Ovarian Clear Cell Tumors Associated With Seromucinous Borderline Tumor: A Case Series. International Journal of Gynecological Pathology, 2022, 41, 76-81.	1.4	7
248	Metastatic Neoplasms Involving the Ovary. Surgical Pathology Clinics, 2011, 4, 297-330.	1.7	6
249	Myoepithelioma of the Ovary. International Journal of Gynecological Pathology, 2014, 33, 191-196.	1.4	6
250	Ovarian hilar proliferations resembling Sertoli cell tumours: microscopic neoplasms or nonâ€neoplastic remnants?. Histopathology, 2016, 68, 596-602.	2.9	6
251	Identical <i><scp>TP</scp>53</i> mutations provide evidence that lateâ€recurring tuboâ€ovarian highâ€grade serous carcinomas do not represent new peritoneal primaries. Histopathology, 2017, 71, 1014-1017.	2.9	6
252	BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma. International Journal of Gynecological Cancer, 2018, 28, 472-478.	2.5	6

#	Article	IF	CITATIONS
253	Cervical Squamous Carcinomas With Prominent Acantholysis and Areas Resembling Breast Lobular Carcinoma: An Aggressive Form of Dedifferentation. International Journal of Gynecological Pathology, 2018, 37, 74-81.	1.4	6
254	Macroscopy under the microscope: a critical reappraisal of grossing techniques. Histopathology, 2020, 76, 930-933.	2.9	6
255	Uterine Adenosarcoma Originating in Adenomyosis: Report of an Extremely Rare Phenomenon and Review of Published Literature. International Journal of Gynecological Pathology, 2021, 40, 342-348.	1.4	6
256	Endometrial neuroendocrine carcinoma and undifferentiated carcinoma are distinct entities with overlap in neuroendocrine marker expression. Histopathology, 2022, 81, 44-54.	2.9	6
257	Neuroectodermal elements are part of the morphological spectrum of DICER1-associated neoplasms. Human Pathology, 2022, 123, 46-58.	2.0	6
258	The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 201-212.	2.8	6
259	Pitfalls in the diagnosis of endometriosis: a condition characterized by a plethora of unusual histological features. Diagnostic Histopathology, 2011, 17, 193-202.	0.4	5
260	The central role of the pathologist in the management of patients with cervical cancer: ESGO/ESTRO/ESP guidelines. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 45-54.	2.8	5
261	The evolving spectrum of endocervical adenocarcinoma in situ (AIS). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 485-486.	2.8	5
262	Spindle Cell Sarcoma of the Uterine Corpus With Adipose Metaplasia: Expanding the Morphologic Spectrum of Neoplasms With MEIS1-NCOA2 Gene Fusion. International Journal of Gynecological Pathology, 2022, 41, 417-422.	1.4	5
263	The impact of the COVID-19 pandemic on endometrial cancer and endometrial hyperplasia diagnoses: a population-based study. American Journal of Obstetrics and Gynecology, 2022, 226, 737-739.e2.	1.3	5
264	Endometrial Involvement in Pseudomyxoma Peritonei Secondary to Low-Grade Appendiceal Mucinous Neoplasm. International Journal of Gynecological Pathology, 2015, 34, 232-238.	1.4	4
265	Vulval Microglandular Adenosis-like Neoplasm With Chondromyxoid Stroma. International Journal of Gynecological Pathology, 2016, 35, 123-126.	1.4	4
266	Vulvovaginal mesenchymal lesions: a review and update. Diagnostic Histopathology, 2018, 24, 1-17.	0.4	4
267	Fibroadenoma-like Lesion of the Vagina. International Journal of Gynecological Pathology, 2018, 37, 141-146.	1.4	4
268	p16 Immunoreactivity Correlates With Morphologic Diagnosis of HPV-associated Anal Intraepithelial Neoplasia. American Journal of Surgical Pathology, 2021, 45, 1573-1578.	3.7	4
269	Recurrent KAT6B/A::KANSL1 Fusions Characterize a Potentially Aggressive Uterine Sarcoma Morphologically Overlapping With Low-grade Endometrial Stromal Sarcoma. American Journal of Surgical Pathology, 2022, 46, 1298-1308.	3.7	4
270	Borderline Ovarian Mucinous Neoplasm Recurring as Small Cell Carcinoma of Hypercalcemic Type. International Journal of Gynecological Pathology, 2011, 30, 380-385.	1.4	3

#	Article	IF	CITATIONS
271	Primary Ovarian High-grade Neuroendocrine Carcinoma With Merkel Cell–like Immunophenotype Arising in a Teratoma. International Journal of Gynecological Pathology, 2020, 39, 478-484.	1.4	3
272	Vulvovaginal Mesenchymal Lesions. , 2013, , 207-243.		3
273	NiCCC (ENGOT-GYN1): A randomized phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear-cell carcinoma of the ovary or endometrium Journal of Clinical Oncology, 2016, 34, TPS5603-TPS5603.	1.6	3
274	A Subset of <scp>SMARCB1</scp> ( <scp>INI</scp> â€1)â€deficient vulvar neoplasms express germ cell markers. Histopathology, 2022, 81, 342-351.	2.9	3
275	Ovarian borderline tumours: a review with emphasis on controversial areas. Diagnostic Histopathology, 2011, 17, 178-192.	0.4	2
276	Carcinosarcoma Arising in a Uterine Leiomyoma. International Journal of Gynecological Pathology, 2011, 30, 576-580.	1.4	2
277	Re: The Revised FIGO Staging System for Uterine Malignancies: Implications for MR Imaging. Radiographics, 2013, 33, 1520-1521.	3.3	2
278	High-risk human papillomavirus (HPV) detection in formalin-fixed paraffin-embedded cervical tissues: performances of Aptima HPV assay and Beckton Dickinson (BD) Onclarity assay. Journal of Clinical Pathology, 2021, , jclinpath-2021-207657.	2.0	2
279	Pelvic and Ovarian Recurrence of Small HPV-associated Cervical Adenocarcinoma With Transformation to Neuroendocrine Carcinoma. International Journal of Gynecological Pathology, 2021, 40, 541-548.	1.4	2
280	Late Development of Metastatic Ovarian Mucinous Adenocarcinoma From Primary Gallblader Adenocarcinoma and High-grade Dysplasia. International Journal of Gynecological Pathology, 2021, 40, 41-48.	1.4	2
281	Immunohistochemical Markers of Value in the Diagnosis of Mesenchymal Lesions of the Female Genital Tract. Surgical Pathology Clinics, 2009, 2, 785-811.	1.7	1
282	Morphological sub-types of ovarian carcinoma: new developments and pathogenesis. , 0, , 3-16.		1
283	Gynaecological pathology: problematic areas, new concepts and emerging developments. Pathology, 2018, 50, 119-121.	0.6	1
284	Primary fallopian tube sex cord tumour: tubal counterpart of uterine tumour resembling ovarian sex cord tumour. Histopathology, 2018, 73, 175-178.	2.9	1
285	KRAS-mutated Uterine Endometrioid Carcinoma With Extensive Surface Changes Resulting in Striking Morphologic Mimicry of an Ovarian Serous Borderline Tumor. International Journal of Gynecological Pathology, 2020, 39, 573-577.	1.4	1
286	An Unusual Enteric Yolk Sac Tumor. International Journal of Gynecological Pathology, 2021, Publish Ahead of Print, .	1.4	1
287	Platinum based chemotherapy selects for PDGFRα dependent angiogenesis Journal of Clinical Oncology, 2018, 36, 5578-5578.	1.6	1
288	Data Set for the Reporting of Carcinomas of the Vagina: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International Journal of Gynecological Pathology, 0, Publish Ahead of Print, .	1.4	1

#	Article	IF	CITATIONS
289	Gynecologic Pathology. Surgical Pathology Clinics, 2016, 9, ix-x.	1.7	0
290	Immunohistochemistry and Molecular Diagnostics in the Differential Diagnosis of Female Genital Tract Pathology. , 2020, , 905-958.		0
291	β atenin signatures in the fallopian tube: an emerging concept. Histopathology, 2020, 77, 877-879.	2.9	0
292	Survey Results on Pathologic Aspects of Endocervical Adenocarcinoma by the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology, 2021, 40, S4-S13.	1.4	0
293	COVID-19 pandemic: unexpected problems in pathological reporting. Journal of Clinical Pathology, 2021, 74, 820-820.	2.0	0
294	Tuboâ€Ovarian Highâ€Grade Serous Carcinomas Commonly Express CA19.9. Histopathology, 2021, , .	2.9	0
295	Cervical stromal involvement by endometrial â€~hyperplasia': a previously unreported phenomenon with recommendations to report as stage II endometrial carcinoma. Pathology, 2021, 53, 568-573.	0.6	0
296	Cervical Small Cell Variant of Paraganglioma With Sarcomatous Transformation. International Journal of Gynecological Pathology, 2021, Publish Ahead of Print, .	1.4	0
297	Cervix. , 2013, , 251-259.		0
298	Fallopian Tube. , 2013, , 235-239.		0
299	Uterus. , 2013, , 241-250.		0
300	Other Neoplasms of the Cervix. , 2014, , 113-133.		0
301	Ovary. , 2017, , 243-253.		0
302	Fallopian Tube. , 2017, , 255-259.		0
303	Uterus. , 2017, , 261-271.		0
304	Vulva. , 2017, , 289-294.		0
305	Mesenchymal and Mixed Epithelial-Mesenchymal Neoplasms of the Cervix. , 2017, , 201-211.		0

#	Article	IF	CITATIONS
307	Title is missing!. , 2020, 15, e0232231.		0
308	Title is missing!. , 2020, 15, e0232231.		0
309	Title is missing!. , 2020, 15, e0232231.		0
310	A bespoke target selection tool to guide biomarker discovery in tubo-ovarian cancer. Computational and Structural Biotechnology Journal, 2022, 20, 3359-3371.	4.1	0